Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

June Abadilla

Internal Medicine Jackson, KY Medical Doctor

NPI 1811975683 CMS profile 127817

12 Jackson Hts, Jackson, KY 41339

Open in the dashboard

General payments

$9,773

479 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, June Abadilla of Jackson, KY is reported in the CMS Open Payments database as having received $9,773 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,044 137
2024 General $2,468 104
2023 General $1,608 86
2022 General $1,058 51
2021 General $767 44
2020 General $350 22
2019 General $478 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • June Abadilla
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to June Abadilla were reported at $3,044. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year June Abadilla Internal Medicine median Middle half National median
2019 $478 $159 $48–$570 $163
2020 $350 $119 $33–$402 $114
2021 $767 $135 $37–$521 $132
2022 $1,058 $141 $42–$496 $149
2023 $1,608 $149 $45–$519 $160
2024 $2,468 $154 $47–$537 $164
2025 $3,044 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,986 65 payments
  2. Lilly USA, LLC $1,285 73 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,201 54 payments
  4. Novo Nordisk Inc $771 50 payments
  5. GlaxoSmithKline, LLC. $753 49 payments
  6. Electromed, Inc. $584 26 payments
  7. Grifols USA, LLC $479 21 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $389 20 payments
  9. Genzyme Corporation $296 11 payments
  10. Philips Electronics North America Corporation $253 16 payments
  11. Other $1,776 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,639 473 payments
  2. Education $134 6 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,111 30 payments
  2. JARDIANCE $874 31 payments
  3. MOUNJARO $728 43 payments
  4. TRELEGY ELLIPTA $653 41 payments
  5. BREZTRI $640 13 payments
  6. Ozempic $627 35 payments
  7. SMARTVEST $584 26 payments
  8. RYBELSUS $475 32 payments
  9. LOKELMA $447 6 payments
  10. AIRSUPRA $421 13 payments
  11. Other $5,747 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 209 drugs

Part D claims

16,791

Median for Internal Medicine: 777

Drug cost

$2,816,782

Median for Internal Medicine: $73,373

Branded share of claims

27.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 298 $383,595
Prolastin C Alpha-1-Proteinase Inhibitor Brand 28 $315,452
Ozempic Semaglutide Brand 180 $250,519
Jardiance Empagliflozin Brand 156 $214,669
Eliquis Apixaban Brand 137 $163,436
Zemaira Alpha-1-Proteinase Inhibitor Brand 14 $152,045
Trulicity Dulaglutide Brand 108 $151,718
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 124 $139,596
Farxiga Dapagliflozin Propanediol Brand 98 $123,207
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 106 $105,434

The 10 drugs with the highest cost, of 209 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$1,822

Medicare's payments for the services billed

Medicare patients

48

Average age 74

Services billed

112

26 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Arthritis 56%
COPD 54%
Ischemic heart disease 46%
Heart failure 44%
Chronic kidney disease 29%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $450
$450 156 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $256
$256 17 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $237
$237 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $141
$141 98 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $117
$117 124 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record